BioSpace News Archive

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), is pleased to announce the grant of patent no. 7030750 entitled “Antibody molecules to LAG-3 and uses thereof” by the Japanese Patent Office.

Melzi Surgical (“Melzi” or the “Company”), a surgical device company dedicated to creating innovative technologies that improve patient outcomes while reducing hospital expenses, announced today that Reid Rutherford, Chief Executive Officer, will present at the Life Science Intelligence (LSI) USA ’22 Emerging Medtech Summit.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share.

MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, reported financial results for the fourth quarter and full year 2021.

Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments across multiple modalities, today announced that members of its executive leadership team will virtually present at the KeyBanc Life Sciences & MedTech Investor Forum at 10:30 a.m. ET on March 23, 2022.

Cynosure LLC announced today that Cynosure KK (subsidiary of Cynosure LLC) has entered into a distribution partnership with Jeisys Medical KK (subsidiary of Jeisys Medical Inc.) in Japan.

Scilex Holding Company (“Scilex”), a majority-owned subsidiary of Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”), today announced highly significant positive final results from its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program.

Incyte (Nasdaq:INCY) today announced that multiple abstracts featuring data from its dermatology portfolio will be presented at the upcoming American Academy of Dermatology (AAD) Annual Meeting.

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today presented data demonstrating the effective prediction of preeclampsia using protein biomarkers and clinical factors.

Recursion first patient in its Phase 2 SYCAMORE clinical trial evaluating REC-994, a potentially first-in-class, orally bioavailable small molecule for the treatment of CCM.